NIVF (NIVF) Stock Analysis

Verdict: AVOID

Severe equity dilution from a $1.25M offering at $0.07 destroys shareholder value amid heavy burn and severe delisting risk.

Investment score: 14/100

Is NIVF Stock Worth Reviewing? AI Model Thesis

The AI model recommends AVOID for NewGenIvf Group Ltd (NIVF). The company's recent pricing of a $1.25 million public offering at $0.07 per share caused a 79.12% price collapse, highlighting critical solvency and liquidity risks.

Should You Buy or Sell NIVF Stock? Model Reasoning

The model strongly views NIVF as an urgent avoid due to a dramatic 79.12% single-day crash following a heavily dilutive $1.25M public offering at $0.07 per share. With a microcap market capitalization of $0.78M and 2025 operating cash flow of -$10.93M against only $0.76M in cash, the capital raise offers only a brief runway while severely diluting equity holders.

NIVF Fair Value & Price Target — AI Valuation

  • Model Assumptions: ["Operating cash outflow continues at an annualized rate exceeding $8.0M against less than $2.0M in combined cash liquidity.","Further dilutive equity issuances will be required within 3-6 months to maintain operational continuity.","Net income swings (such as $9.88M in 2025) stem from non-operating valuation adjustments rather than sustainable clinic operational profits."]

NIVF Risk & Opportunity Analysis

Key Investment Risks

  • Catastrophic Equity Dilution from $1.25M Public Offering — The issuance of 17.86M new shares/warrants at $0.07 per share drastically expands the share count relative to the previous base, crippling book value per share.
  • Exhaustion of Cash Reserves Within Months — With 2025 operating cash burn at -$10.93M, the new $1.25M capital raise represents less than 45 days of operating cash, forcing additional dilution before mid-2027.
  • NASDAQ Delisting and Reverse Split Hazard — Sustained trading below $1.00 ($0.072 currently) triggers NASDAQ deficiency notices, making a 1-for-20 or larger reverse stock split almost inevitable by Q1 2027.
  • Severe Liquidity and Trading Slippage Risk — With a market cap under $1 million, low trading liquidity makes entering or exiting meaningful positions without significant price slippage virtually impossible.

Growth Opportunities & Upside Drivers

  • Capital Injection Extends Short-Term Cash Runway — The $1.25 million gross proceeds from the September 29, 2026 public offering provide emergency cash to cover immediate operating expenses through Q4 2026.
  • Regional Demand Growth for Reproductive Services in Southeast Asia — Expanding fertility tourism in Thailand could support revenue recovery beyond 2026 if operational restructuring reduces the severe -$10.73M operating deficit recorded in 2025.
  • Historical Insider Accumulation by Key Executives — Director Cheung Kong Yiu purchased 3.5 million shares between May and July 2026 at prices ranging from $1.00 to $1.50, indicating long-term insider alignment despite current distress.
  • Potential Volatility Spikes for Speculative Bounce Traders — High retail interest following an 80% single-day collapse can trigger short-lived technical relief rallies above the $0.07 offering floor.

NIVF Action Plan — Entry, Exit and Stop Loss from the Model View

moderate

    aggressive

      conservative

        Frequently Asked Questions About NIVF (NIVF)

        Is NIVF stock a good investment?

        The cached TradeMates AI model rates NIVF as AVOID with an investment score of 14/100. The AI model recommends AVOID for NewGenIvf Group Ltd (NIVF). The company's recent pricing of a $1.25 million public offering at $0.07 per share caused a 79.12% price collapse, highlighting critical solvency and liquidity risks. This is algorithmic model output, not personal investment advice.

        Does NIVF pay a dividend?

        The cached stock data on this page does not show a positive dividend yield for NIVF. Dividend status can change, so verify the latest company filings before relying on income assumptions.

        What does NIVF stock do?

        NewGenIvf provides assisted reproductive technology (ART) services, including in-vitro fertilization (IVF), egg donation, surrogacy, and ancillary fertility treatments operating out of clinics in Thailand.

        What is NIVF stock's price target?

        This cached page does not contain a precise model fair value for NIVF.

        Is NIVF stock a buy?

        The TradeMates model verdict for NIVF is AVOID with an investment score of 14/100. Treat this as a model signal to review, not a personal buy recommendation.

        Is NIVF a good dividend stock?

        NIVF is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

        View the full interactive analysis